| Title |
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
|
|---|---|
| Published in |
Radiation Oncology, May 2016
|
| DOI | 10.1186/s13014-016-0644-4 |
| Pubmed ID | |
| Authors |
Henry W. C. Leung, Chung-Feng Liu, Agnes L. F. Chan |
| Abstract |
Stereotactic body radiotherapy (SBRT) has been shown to improve overall survival in patients with advanced hepatocellular carcinoma. This study aimed to assess the cost-effectiveness of SBRT compared to sorafenib which is the only drug for advanced hepatocellular carcinoma. A Markov decision-analytic model was performed to compare the cost-effectiveness of SBRT and sorafenib for unresectable advanced hepatocellular carcinoma. Patients transitioned between three health states: stable disease, progression disease and death. We calculated the data on cost from the perspective of our National Health Insurance Bureau. Sensitivity analyses were conducted to determine the impact of several variables. The incremental cost effectiveness ratio (ICER) for sorafenib compared to SBRT was NT$3,788,238 per quality-adjusted life year gained (cost/QALY), which was higher than the willingness to pay threshold of Taiwan according to WHO's guideline. One-way sensitivity analysis revealed that the utility of progression disease for the sorafenib treatment, utility of progression free survival for SBRT, utility of progression free survival for sorafenib, utility of PFS to progression disease for SBRT and transition probability of progression disease to dead for SBRT were the most sensitive parameters in all cost scenarios. The Monte-Carlo simulation demonstrated that the probability of cost-effectiveness at a willingness to pay threshold of NT$ 2,213,145 per QALY was 100 % and 0 % chance for SBRT and sorafenib. This study indicated that SBRT for advanced hepatocellular carcinoma is cost-effective at a willingness to pay threshold as defined by WHO guideline in Taiwan. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 5 | 45% |
| Turkey | 1 | 9% |
| Philippines | 1 | 9% |
| United Kingdom | 1 | 9% |
| Unknown | 3 | 27% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 82% |
| Practitioners (doctors, other healthcare professionals) | 1 | 9% |
| Scientists | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Unknown | 72 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 18% |
| Other | 10 | 14% |
| Student > Doctoral Student | 8 | 11% |
| Lecturer | 6 | 8% |
| Student > Master | 6 | 8% |
| Other | 15 | 21% |
| Unknown | 15 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Nursing and Health Professions | 6 | 8% |
| Agricultural and Biological Sciences | 3 | 4% |
| Economics, Econometrics and Finance | 3 | 4% |
| Other | 8 | 11% |
| Unknown | 18 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2017.
All research outputs
#3,590,647
of 22,870,727 outputs
Outputs from Radiation Oncology
#107
of 2,058 outputs
Outputs of similar age
#62,337
of 334,246 outputs
Outputs of similar age from Radiation Oncology
#3
of 37 outputs
Altmetric has tracked 22,870,727 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,058 research outputs from this source. They receive a mean Attention Score of 2.7. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,246 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.